Synthetic Biologics, Inc. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today the […]
In a new study, researchers at the University of Maryland School of Medicine (UMSOM) have found that the gut microbiome appears to play a key role in how well the body accepts a transplanted heart. […]
Valbiotis, a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former Executive Director of Biofortis Mérieux […]
DNAnexus, the global leader in biomedical informatics and data management, today announced the winners of the Mosaic Community Challenge: Clinical Strain Detection, which evaluated the accuracy of microbial strain detection in metagenomic samples. The challenge […]
Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases (ILD). In a study at CHEST 2018, researchers at Beaumont Health Systems studied the influence of bacterial virulence on […]
Vedanta Biosciences announced preliminary results from the Phase 1a/1b clinical study in healthy volunteers for its lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI), VE303. With these Phase 1 data […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, […]
Pivot Bio announced today $70 million in a Series B funding round led by Breakthrough Energy Ventures, and includes Singapore-headquartered investment company, Temasek. This funding further strengthens Pivot Bio’s 2019 commercial launch of the first […]
Following A-Mansia’s announcement of first close of Series A this April, Innovation Industries now joins the financing round of the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. […]
Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the […]
The DuPont Microbiome Venture and Global Health & Nutrition Science teams have worked in collaboration with the University of Virginia and 4Pharma Ltd in an experimental rhinovirus challenge to understand the role of nasal microbiota clusters and their […]